CN116601149A - 作为p2x3抑制剂的氨基喹唑啉衍生物 - Google Patents
作为p2x3抑制剂的氨基喹唑啉衍生物 Download PDFInfo
- Publication number
- CN116601149A CN116601149A CN202180079588.2A CN202180079588A CN116601149A CN 116601149 A CN116601149 A CN 116601149A CN 202180079588 A CN202180079588 A CN 202180079588A CN 116601149 A CN116601149 A CN 116601149A
- Authority
- CN
- China
- Prior art keywords
- fluorophenyl
- methyl
- alkyl
- quinazolin
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20210189.5 | 2020-11-27 | ||
| EP20210189 | 2020-11-27 | ||
| PCT/EP2021/083141 WO2022112490A1 (en) | 2020-11-27 | 2021-11-26 | Amino quinazoline derivatives as p2x3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116601149A true CN116601149A (zh) | 2023-08-15 |
Family
ID=73642588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180079588.2A Pending CN116601149A (zh) | 2020-11-27 | 2021-11-26 | 作为p2x3抑制剂的氨基喹唑啉衍生物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240025880A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4251620B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7844468B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230113309A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116601149A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021388923A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3196333A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3026309T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023005803A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022112490A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026517300A (ja) | 2023-05-22 | 2026-05-28 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | P2x3阻害剤を調製するための方法および中間体 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110009432A1 (en) * | 2007-04-02 | 2011-01-13 | Zhi-Liang Wei | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof |
| CN113891745A (zh) * | 2019-05-31 | 2022-01-04 | 奇斯药制品公司 | 作为p2x3抑制剂的氨基喹唑啉衍生物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2596706T3 (es) | 2006-06-29 | 2017-01-11 | F. Hoffmann-La Roche Ag | Arilamidas con sustitución de tetrazol |
| US8076345B2 (en) | 2007-04-17 | 2011-12-13 | Evotec Ag | 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof |
| WO2009110985A2 (en) | 2008-02-29 | 2009-09-11 | Renovis, Inc. | Amide compounds, compositions and uses thereof |
| US20110237578A1 (en) | 2008-09-18 | 2011-09-29 | Zhi-Liang Wei | Amide compounds, compositions and uses thereof |
| WO2016084922A1 (ja) | 2014-11-28 | 2016-06-02 | 塩野義製薬株式会社 | 1,2,4-トリアジン誘導体およびその医薬組成物 |
| WO2016088838A1 (ja) | 2014-12-04 | 2016-06-09 | 塩野義製薬株式会社 | プリン誘導体およびその医薬組成物 |
| CU24411B1 (es) | 2014-12-09 | 2019-05-03 | Bayer Ag | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos |
| WO2017011729A1 (en) | 2015-07-16 | 2017-01-19 | Patara Pharma, LLC | Combination therapies for the treatment of lung diseases |
| CA2998742C (en) | 2015-09-29 | 2023-08-29 | Anthony P. FORD | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
-
2021
- 2021-11-26 WO PCT/EP2021/083141 patent/WO2022112490A1/en not_active Ceased
- 2021-11-26 AU AU2021388923A patent/AU2021388923A1/en active Pending
- 2021-11-26 KR KR1020237018300A patent/KR20230113309A/ko active Pending
- 2021-11-26 US US18/038,744 patent/US20240025880A1/en active Pending
- 2021-11-26 JP JP2023532331A patent/JP7844468B2/ja active Active
- 2021-11-26 CN CN202180079588.2A patent/CN116601149A/zh active Pending
- 2021-11-26 EP EP21811098.9A patent/EP4251620B1/en active Active
- 2021-11-26 ES ES21811098T patent/ES3026309T3/es active Active
- 2021-11-26 MX MX2023005803A patent/MX2023005803A/es unknown
- 2021-11-26 CA CA3196333A patent/CA3196333A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110009432A1 (en) * | 2007-04-02 | 2011-01-13 | Zhi-Liang Wei | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof |
| CN113891745A (zh) * | 2019-05-31 | 2022-01-04 | 奇斯药制品公司 | 作为p2x3抑制剂的氨基喹唑啉衍生物 |
| CN114269432A (zh) * | 2019-05-31 | 2022-04-01 | 奇斯药制品公司 | 作为p2x3抑制剂的氨基喹唑啉衍生物 |
Non-Patent Citations (1)
| Title |
|---|
| GÁBOR SZÁNTÓ等: "New P2X3 receptor antagonists. Part 2: Identification and SAR of quinazolinones", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 26, no. 16, 6 July 2016 (2016-07-06), pages 3905 - 3912, XP029663839, DOI: 10.1016/j.bmcl.2016.07.013 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023005803A (es) | 2023-05-29 |
| EP4251620B1 (en) | 2025-04-16 |
| EP4251620C0 (en) | 2025-04-16 |
| US20240025880A1 (en) | 2024-01-25 |
| AU2021388923A9 (en) | 2024-02-08 |
| WO2022112490A1 (en) | 2022-06-02 |
| ES3026309T3 (en) | 2025-06-11 |
| CA3196333A1 (en) | 2022-06-02 |
| JP2023550840A (ja) | 2023-12-05 |
| KR20230113309A (ko) | 2023-07-28 |
| JP7844468B2 (ja) | 2026-04-13 |
| AU2021388923A1 (en) | 2023-05-25 |
| EP4251620A1 (en) | 2023-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113891745B (zh) | 作为p2x3抑制剂的氨基喹唑啉衍生物 | |
| CN116745284A (zh) | 作为p2x3抑制剂的酞嗪衍生物 | |
| EP4251617B1 (en) | (aza)quinoline 4-amines derivatives as p2x3 inhibitors | |
| ES3026309T3 (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| RU2821714C2 (ru) | Производные аминохиназолина в качестве p2x3 ингибиторов | |
| HK40089089A (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| RU2833037C2 (ru) | Производные пиридопиримидинов в качестве ингибиторов p2x3 | |
| HK40106991A (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| HK40062196B (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| HK40057265A (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| HK40057265B (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| HK40062196A (en) | Amino quinazoline derivatives as p2x3 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40089089 Country of ref document: HK |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |